A summary of a recent publication in The Journal of Biotechniques showing the utility of Horizon's synthetic sgRNA for CRISPR mediated transcriptional activation studies.
Can base editing move cancer cell therapy further towards off-the-shelf treatments?
Horizon's new Cell free DNA formulated in synthetic matrix reference offers greater compatibility with commonly used cfDNA extraction kits.
Liquid biopsy holds many advantages over solid tumor testing of cancer patients. It is less invasive for the patient, avoiding the need for surgical biopsy, and has improved levels of sensitivity to detect low frequency somatic driver mutations.
Here we discuss a recent paper by Gisela Jimenez-Duran and colleagues highlighting how a whole genome CRISPR knockout screen, carried out by Horizon Discovery, has enabled identification of a pre-existing inhibitor that can regulate pro-inflammatory macrophages.
Thinking about doing CRISPR screening for knock out, CRISPR activation or CRISPRi applications? Unsure whether a synthetic arrayed or pooled lentiviral screening library is best for your project? We are here to help.
A roundtable discussion with several of the women scientists at Horizon Discovery's Boulder office sharing personal reflections after Jennifer Doudna along with Emmanuelle Charpentier won the Nobel Prize in Chemistry this year.
This article briefly describes how our reference standards are produced and the quality control measures to ensure the standards are reliable from batch to batch.
Here are some essential points to think about when ordering your oligos for in vivo experiments.
A summary of a recent publication in The CRISPR Journal showing that Horizon's integrated pooled CRISPRko and high throughput cell panel screening platform together offer clinically relevant information for therapeutic targets.